As expected, the new drug Nuplazid (pimavanserin) marketed by Acadia pharmaceuticals has been approved by the FDA. This drug is for the treatment of hallucinations and psychosis in Parkinson's disease patients. It is expected to be prescribed off-label for Lewy Body Dementia patients. (At this time, all drugs to treat LBD are considered "off-label") The company is in the process of advising medical professionals about prescribing the medication and what the contraindications exist for not using the drug.
Below is the press release announcement -- it is a gov link so I hope it is OK. You can easily also just do a google search to find out more about the drug.